Drug Combination Details
General Information of the Combination (ID: C53884) | |||||
---|---|---|---|---|---|
Name | Vincristine NP Info | + | VE-465 Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M-phase | ||||
In-vitro Model | KCL-22 | CVCL_2091 | Chronic myelogenous leukemia | Homo sapiens | ||
K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
Ku812 | CVCL_0379 | Chronic myelogenous leukemia | Homo sapiens | |||
THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
KY821 | CVCL_1346 | Acute myelomonocytic leukemia | Homo sapiens | |||
Experimental
Result(s) |
Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. |
References | ||||
---|---|---|---|---|
Reference 1 | Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. Biochem Pharmacol. 2011 Dec 15;82(12):1884-90. |







